Loading clinical trials...
Loading clinical trials...
A Phase I, Open Label, Dose-Escalation, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR106 in Patients With Select Relapsed Advanced Malignancies (JIVAN)
Conditions
Interventions
AUR106
Locations
6
India
Omega Hospital
Visakhapatnam, Andhra Pradesh, India
Unique Hospital Multispeciality and Research Institute
Surat, Gujarat, India
Kiran Multi Super Specialty Hospital
Surat, Gujarat, India
Sankalp Speciality Hospital
Nashik, Maharashtra, India
Moraya Multispeciality Hospital (Ashwin Medical Foundations)
Pune, Maharasthra, India
All India Institute of Medical Sciences
Bhubaneswar, Odisha, India
Start Date
August 26, 2023
Primary Completion Date
February 10, 2026
Completion Date
February 10, 2026
Last Updated
April 17, 2026
NCT05671510
NCT07320235
NCT03340506
NCT05865002
NCT03618550
NCT06721689
Lead Sponsor
Aurigene Discovery Technologies Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions